BRISTOL-MYERS SQUIBB COMPANY Deferred Tax Assets, Operating Loss Carryforwards, Foreign
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Deferred Tax Assets, Operating Loss Carryforwards, Foreign of $1.23 billion as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign · last filed 2026-02-11
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $1.23B.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $1.52B.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $2.02B.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Foreign $566.00M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Foreign |
|---|---|
| 2025-12-31 | $1.23B 10-K · filed 2026-02-11 |
| 2024-12-31 | $1.52B 10-K · filed 2026-02-11 |
| 2023-12-31 | $2.02B 10-K · filed 2025-02-12 |
| 2022-12-31 | $566.00M 10-K · filed 2024-02-13 |
| 2021-12-31 | $945.00M 10-K · filed 2023-02-14 |
| 2020-12-31 | $3.27B 10-K · filed 2022-02-09 |
| 2019-12-31 | $2.48B 10-K · filed 2021-02-10 |
| 2018-12-31 | $2.98B 10-K · filed 2020-02-24 |
| 2017-12-31 | $2.87B 10-K · filed 2019-02-25 |
| 2016-12-31 | $2.94B 10-K · filed 2018-02-13 |
| 2015-12-31 | $3.09B 10-K · filed 2017-02-21 |
| 2014-12-31 | $3.47B 10-K · filed 2016-02-12 |
| 2013-12-31 | $3.89B 10-K · filed 2015-02-13 |
| 2012-12-31 | $3.72B 10-K · filed 2014-02-14 |
| 2011-12-31 | $3.67B 10-K · filed 2013-02-15 |
| 2010-12-31 | $1.60B 10-K · filed 2012-02-17 |
| 2009-12-31 | $1.48B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |